Sharps Technology (STSS) Registration Filing summary

Company overview and business model

• Operates as a medical device sales and distribution enterprise, focusing on syringes and drug-delivery systems for clinical and specialty applications.

• Recently adopted a digital asset treasury strategy centered on accumulating Solana (SOL) and generating on-chain yield.

• Plans to expand distribution by representing third-party manufacturers of complementary medical products.

• Committed to regulatory compliance with FDA and international standards.

• Exploring strategic acquisitions and digital product development globally.

Financial performance and metrics

• Closed a $400 million PIPE (Private Investment in Public Equity) offering in August 2025, using proceeds to acquire over 2,000,000 SOL.

• As of December 15, 2025, 28,995,402 shares of common stock were outstanding, with significant additional shares issuable upon exercise of warrants and options.

Use of proceeds and capital allocation

• Proceeds from securities sales may be used for debt repayment, share repurchases, working capital, capital expenditures, acquisitions, and further implementation of the SOL Treasury Policy.

• Board-approved share repurchase program authorizes up to $100 million in buybacks.

• May use proceeds to purchase additional SOL or fund business expansion.